CARD11 Gene Immunodeficiency Type 11 Genetic Test in UAE | 2,800 AED | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).

Premium Logistics: Paid hospital-grade home collection via ISO-certified cold-chain transport and VIP mobile phlebotomy.

Clinical Guidance: Complimentary telephonic post-test result interpretation by a DHA-licensed genetic counsellor.

Insurance & Billing: Direct insurance verification via WhatsApp: +971545488731.

Test Overview & Methodology

The CARD11 Gene Immunodeficiency Type 11 NGS Test is a high-resolution genetic analysis designed to detect pathogenic variants in the CARD11 gene, which causes autosomal dominant immunodeficiency 11 (also known as combined immunodeficiency with severe atopy). This test is indicated for individuals with early-onset eczema, recurrent severe infections, and atypical immunological profiles, providing definitive molecular confirmation for clinical management and family screening.

Feature	Our CARD11 NGS Test	Closest Alternative (WES)
Methodology	Targeted NGS (Illumina NovaSeq) with 100% coverage of coding regions and canonical splice sites	Whole Exome Sequencing (partial coverage; may miss deep intronic variants)
Turnaround Time	3–4 Weeks	6–10 Weeks
Variant Interpretation	ACMG/AMP Variant Interpretation Guidelines with DHA-approved pathogenicity scoring	Broader, less targeted analytics with variable coverage
Price	2,800 AED	4,500 AED (average)

Physician Insight & Safety Protocols

“Genetic confirmation of a CARD11 pathogenic variant establishes a definitive diagnosis of immunodeficiency 11, allowing for tailored therapeutic interventions ranging from targeted immunomodulation to hematopoietic stem cell transplantation. The interpretation of genetic results must always be integrated with the patient's clinical presentation and family pedigree. Our dedicated team is here to provide comprehensive support throughout the testing and counselling process.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication & Treatment Considerations

Do not modify or discontinue any prescribed immunosuppressive, corticosteroid, or antimicrobial therapy without prior consultation with your treating physician. Treatment adjustments should be based on clinical assessment and laboratory correlation rather than the genetic testing process itself. The DNA analysis remains unaffected by current medication status.

Exclusion Criteria & Safety Red Flags

Exclusion: Known contraindication to venipuncture (e.g., severe coagulopathy). Alternative DNA FTA card collection is available upon request.
Exclusion: Active systemic infection requiring hospitalisation — postpone until stabilised, unless deemed urgent by the managing physician.
ER Red Flag: If you experience profuse bleeding, large haematoma, or signs of infection at the phlebotomy site, seek immediate medical attention.
ER Red Flag: Sudden severe respiratory distress, chest pain, or high fever — proceed to the nearest emergency department for evaluation of a potential immunological crisis unrelated to the blood draw.

Patient FAQ & Clinical Guidance

1. What preparation is required for the CARD11 Genetic Test?

No fasting is required. Please inform your phlebotomist of any anticoagulant or antiplatelet medications to minimise bruising. The test analyses your DNA, so current medications do not alter the genetic result.

2. How long does it take to receive the results?

Results are typically finalised within 3 to 4 weeks, reflecting the rigorous sequencing, bioinformatics, and clinical variant interpretation processes that ensure diagnostic precision.

3. What does a positive CARD11 result mean for me and my family?

A positive result confirms a pathogenic CARD11 gene variant associated with autosomal dominant immunodeficiency 11, which mandates genetic counselling for relatives and may influence treatment choices such as prophylactic antibiotics or haematopoietic stem cell transplantation.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under DHA Facility License No. 1143. All genetic testing services comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) confirms quality management for medical testing.

Genetic testing requires informed consent. Results are for clinical purposes only and must be interpreted by a qualified healthcare professional.

Clinical & Logistical Metadata

Test Name	CARD11 Gene Immunodeficiency Type 11 Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood
Methodology Used	Targeted Next-Generation Sequencing (NGS) – Illumina NovaSeq
ICD-10-CM Code	D81.89
LOINC Code	96601-4
DHA Facility License & Laboratory Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE